Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast...

Area of Science:

• Oncology
• Molecular Biology
• Bone Biology

Background:

• Bone morphogenetic proteins (BMPs) and their receptors are implicated in osteolytic metastasis of breast cancer.
• The role of BMP receptors in tumor-stromal interactions, particularly in breast cancer bone metastasis, remains largely unexplored.

Purpose of the Study:

• To investigate the role of BMP receptor type 1a (BMPR1a) in mediating the interaction between metastatic breast cancer cells and osteoclast precursors.
• To determine if BMPR1a influences the development of osteolytic bone lesions in breast cancer metastasis.

Main Methods:

• Adenovirus-mediated RNA interference was employed to knockdown BMPR1a in human breast cancer cell lines (MDA-MB-231-luc, MCF-7).
• Intratibial injection of cancer cells into nude mice models for evaluating tumor growth and bone destruction using bioluminescence imaging and microCT.
• Analysis of gene and protein expression (RANKL, p38) using RT-PCR, Western blotting, and ELISA.
• In vitro osteoclastogenesis assays using murine bone marrow mononuclear cells or RAW264.7 cells.

Main Results:

• BMPR1a expression was higher at the tumor-bone interface compared to distant tumor cells.
• Knockdown of BMPR1a in breast cancer cells significantly reduced tumor growth and bone destruction in vivo.
• BMPR1a knockdown decreased the production of receptor activator for NF-κB ligand (RANKL) in cancer cells, an effect mediated through the p38 pathway.
• Inhibition of p38 or knockdown of BMPR1a suppressed cancer cell-induced osteoclastogenesis.

Conclusions:

• BMPR1a plays a critical role in breast cancer-induced osteolytic metastasis by promoting osteoclastogenesis.
• Targeting BMPR1a in breast cancer cells suppresses RANKL production via the p38 signaling pathway.
• BMPR1a represents a potential therapeutic target for inhibiting breast cancer osteolytic bone metastasis.